Drug Repairs DNA in Early Alzheimer's, Cleared Safety Trials

Scientists at King's College London have discovered that a drug already proven safe in humans can repair the DNA damage that occurs in the earliest stages of Alzheimer's disease.

The drug, called KCL-286, was originally developed for spinal cord injuries and has already cleared Phase 1 human safety trials. Now researchers have found it can tackle multiple features of Alzheimer's at the same time, offering hope for a treatment that goes beyond managing symptoms.

For decades, Alzheimer's research has focused on clearing toxic protein buildups in the brain. But these approaches have had limited success. Scientists are now looking at DNA damage and inflammation, which happen much earlier in the disease process.

Dr. Maria Goncalves, who managed the drug development project, explains that KCL-286 targets both of these early-stage problems. The drug repairs DNA strand breaks while simultaneously reducing inflammation in brain cells.

"DNA double-strand breaks are like a rope snapping completely in two, rather than just fraying at the edges," says Professor Jonathan Corcoran, Professor of Neuroscience at King's College London. KCL-286 promotes repair of these breaks, addressing a key feature that previous treatments have ignored.

The drug works by activating a specific protein pathway that processes vitamin A in the body. Previous studies have linked deficits in this pathway to the formation of harmful protein deposits similar to those seen in Alzheimer's disease.

Why This Inspires

What makes this discovery particularly exciting is the timeline. Because KCL-286 has already proven safe and tolerable in human trials, it can skip years of early-stage testing that new drugs typically require.

The research team tested the drug in mouse models of Alzheimer's and found it reduced multiple disease features at once. This broader approach could be more effective than current treatments that focus on a single aspect of the disease.

Natasha Hill, one of the study's lead authors, emphasizes the importance of tackling multiple aspects of Alzheimer's simultaneously. "KCL-286 was able to target multiple disease-relevant cellular pathways, some of which are initiated very early in the disease course," she says.

The findings represent a shift in how scientists think about treating Alzheimer's, moving from symptom management to potentially modifying the disease itself before severe damage occurs.

With safety trials already complete, this drug could reach patients faster than typical Alzheimer's treatments, bringing hope to millions of families facing this devastating disease.